




PHARMACEUTICAL 2022

Checkpoint Therapeutics Inc.
Rank 376 of 466





PHARMACEUTICAL 2022

Checkpoint Therapeutics Inc.
Rank 376 of 466



The relative strengths and weaknesses of Checkpoint Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Checkpoint Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Checkpoint Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is -13%, being 91% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	55,728
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,982
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	53
Other Revenues	268
Property and Equipment	0
Research and Development	48,453
Selling, General and Administrative Expense	8,538

Output Variable	Value in 1000 USD
Assets	55,728
Liabilities	25,982
Expenses	56,991
Revenues	268
Stockholders Equity	29,746
Net Income	-56,670
Comprehensive Net Income	-56,670
Economic Capital Ratio	-13%